Syndax Pharmaceuticals reports 90% growth in Revuforj quarterly net revenue to $60.7 million
SNDX•Syndax reported third-quarter 2026 revenue of $83.3 million, including Revuforj net revenue of $60.7 million, up 90% year over year, and Niktimvo collaboration revenue of $22.6 million.
1. Third-quarter results
Syndax reported third-quarter 2026 revenue of $83.3 million in its corporate presentation. Its net loss narrowed to $49.4 million from $60.7 million, while Revuforj net revenue rose 90% year over year to $60.7 million and Niktimvo collaboration revenue reached $22.6 million.
2. Cash and pipeline
Cash and equivalents totaled $551.1 million. Full-year R&D and SG&A expense guidance was $400 million, excluding $50 million in expected stock-option expense. A revumenib myelofibrosis trial is expected to begin in the fourth quarter of 2026, with initial data anticipated in the second half of 2027; an investigational new drug application for SNDX-4321 is expected by year-end 2026, and a Phase 1 lung cancer trial is planned for 2027.
